Charles River Laboratories Intl. Inc vs Valero Energy Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while Valero Energy Corporation trades at $434.65 (market cap $127.78B). The key difference: Valero Energy Corporation is far larger — about 9× Charles River Laboratories Intl. Inc's market cap, and Valero Energy Corporation pays a 1.08% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Valero Energy Corporation for 56 Days on average.
| CRL | VLO | |
|---|---|---|
Market Cap | $14.23B | $127.78B |
Volume | 1,176,885 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $310.77 | $443.80 |
52-Week Low | $149.93 | $156.39 |
Typical Hold Time | 33 Days | 56 Days |
Enterprise Value | $17.06B | $131.26B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
Valero Energy (VLO) trades at $433.75, up 2.28% today, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages, though RSI levels suggest overbought conditions. Fundamentally, VLO has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $20.17 EPS. Revenue declined to $122.69B in 2025, but net income margin improved to 5.17%. The company maintains a solid balance sheet with a debt-to-asset ratio of 18.31% as of 2024.
VLO's outlook is supported by robust refining margins and a favorable analyst consensus, with 54% buy ratings and a $408.10 price target. Key risks include potential diesel export bans and volatile energy markets. Investors should weigh strong cash flow projections against cyclical industry headwinds for balanced exposure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →